tetano
Editor, Senior Moderator
Adv Ther. 2020 Apr 29. doi: 10.1007/s12325-020-01351-9. [Epub ahead of print]
Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.
Khan Z[SUP]1,[/SUP][SUP]2[/SUP], Karataş Y[SUP]3,[/SUP][SUP]4[/SUP], Rahman H[SUP]5[/SUP].
Author information
Abstract
The World Health Organization (WHO) called the outbreak of coronavirus infectious disease-2019 (COVID-19) a "Public Health Emergency of International Concern" (PHEIC). According to the WHO, Centers for Disease Control and Prevention (CDC), and the US Food and Drug Administration (FDA), currently there are no medicines or vaccines that have been claimed to be useful in the prevention or treatment of COVID-19. Several existing antiviral drugs, previously developed or used as treatments for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), human immunodeficiency virus (HIV), and malaria, are being investigated as COVID-19 treatments and some of them are being used in clinical trials. According to the CDC and Chinese treatment guidelines for COVID-19, chloroquine, hydroxychloroquine, lopinavir/ritonavir, and one of the investigational agents (remdesivir) are recommended in critically ill older patients. The use of other potential drugs reported in different studies may be considered if treatment with first-line drugs is ineffective. There are currently no complete data available from large randomized clinical trials (RCTs) to provide clinical guidance on the use, dosing, or duration to validate the effective role, safety profile, and adverse effects of all of the trial drugs for prophylaxis or treatment of COVID-19. Until now, it is still unclear which drug can successfully fight against the disease. Therefore, for the better safety of patients with COVID-19, further clinical trials and large randomized controlled studies are needed to validate the effective role, safety profile, and adverse effects of all the potential drugs. Such a measure requires action at the global level.
KEYWORDS:
Adverse effects; China; Chloroquine; Coronavirus infectious disease-2019 (COVID-19); Drugs; MERS; SARS; Therapy
PMID:32350686DOI:10.1007/s12325-020-01351-9
Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.
Khan Z[SUP]1,[/SUP][SUP]2[/SUP], Karataş Y[SUP]3,[/SUP][SUP]4[/SUP], Rahman H[SUP]5[/SUP].
Author information
Abstract
The World Health Organization (WHO) called the outbreak of coronavirus infectious disease-2019 (COVID-19) a "Public Health Emergency of International Concern" (PHEIC). According to the WHO, Centers for Disease Control and Prevention (CDC), and the US Food and Drug Administration (FDA), currently there are no medicines or vaccines that have been claimed to be useful in the prevention or treatment of COVID-19. Several existing antiviral drugs, previously developed or used as treatments for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), human immunodeficiency virus (HIV), and malaria, are being investigated as COVID-19 treatments and some of them are being used in clinical trials. According to the CDC and Chinese treatment guidelines for COVID-19, chloroquine, hydroxychloroquine, lopinavir/ritonavir, and one of the investigational agents (remdesivir) are recommended in critically ill older patients. The use of other potential drugs reported in different studies may be considered if treatment with first-line drugs is ineffective. There are currently no complete data available from large randomized clinical trials (RCTs) to provide clinical guidance on the use, dosing, or duration to validate the effective role, safety profile, and adverse effects of all of the trial drugs for prophylaxis or treatment of COVID-19. Until now, it is still unclear which drug can successfully fight against the disease. Therefore, for the better safety of patients with COVID-19, further clinical trials and large randomized controlled studies are needed to validate the effective role, safety profile, and adverse effects of all the potential drugs. Such a measure requires action at the global level.
KEYWORDS:
Adverse effects; China; Chloroquine; Coronavirus infectious disease-2019 (COVID-19); Drugs; MERS; SARS; Therapy
PMID:32350686DOI:10.1007/s12325-020-01351-9